<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817024</url>
  </required_header>
  <id_info>
    <org_study_id>NNSF90709048</org_study_id>
    <nct_id>NCT00817024</nct_id>
  </id_info>
  <brief_title>Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)</brief_title>
  <official_title>Clinical Study of Herbal Formula in Post PCI Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We conduct this clinical trial to determine the effects of Xuefu Zhuyu capsule (based on TCM
      &quot;Zheng Hou&quot; theory) in helping recovery from coronary heart disease(CHD)after PCI and find
      out whether this kind of effecacy is much better within patients administered with TCM
      syndrome-based individualized medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of a Chinese herbal formulae is not completely based on the disease or some
      biomedical indexes, but much more on the TCM syndrome(Chinese name:Zheng Hou)which is
      generalized from patients' TCM signs and symptoms. Thus, conventional medical curative
      effecacy evaluation system seems not to so fit for TCM clinical studies. Although many
      clinical studies from Chinese literature have reported the beneficial effects of various of
      TCM herbal agents in improving symptoms and signs as well as antagonism of specific
      pathological changes in CHD patients, most of these trials are lack of well-designed
      methodologies and the reliability of results still remains unclear. Therefore, we designed
      this clinical trial, with a randomized, placebo controlled way, to evaluate the curative
      effects of Xuefu Zhuyu capsule(a Chinese herbal medicine)in patients with Post-PCI CHD
      patients and find out whether this effects will be better displayed within subjects
      administered with syndrome-based individualized medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of anginal attacks, alternations of TCM symptoms and signs, and electrocardiographic changes.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life (Hr-QoL); Changes in serum lipid, inflammatory reaction level and endothelial function status alternations before and after the treatment.</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Xuefu Zhuyu Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sheng Mai Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,</intervention_name>
    <description>3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks</description>
    <arm_group_label>Xuefu Zhuyu Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules</intervention_name>
    <description>3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks</description>
    <arm_group_label>Sheng Mai Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules</intervention_name>
    <description>3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years old

          -  Clinical diagnosis of coronary heart disease (confirmed by coronary angiography)

          -  Successfully received interventional therapy (PTCA or PCI)

          -  belong to TCM blood-stasis syndrome

          -  Must be able to swallow tablets

          -  Able to give written informed consent

        Exclusion Criteria:

          -  Symptomatic congestive heart failure(New York Heart Association class III-IV)

          -  Females during pregnancy or lactation

          -  Serious dysfunction in important organs (liver, lung, kidneyï¼Œet al)

          -  Use of concomitant Chinese herbal medicine

          -  Already attend other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guang'an Men Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <name_title>China Academy of Chinese Medical Sciences</name_title>
    <organization>Guang'an Men Hospital</organization>
  </responsible_party>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>PCI</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

